Skip to main page content
U.S. flag
See More

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov 19;330(6007):1066-71.
doi: 10.1126/science.1194396. Epub 2010 Oct 7.

Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists

Beili Wu  1 , Ellen Y T Chien, Clifford D Mol, Gustavo Fenalti, Wei Liu, Vsevolod Katritch, Ruben Abagyan, Alexei Brooun, Peter Wells, F Christopher Bi, Damon J Hamel, Peter Kuhn, Tracy M Handel, Vadim Cherezov, Raymond C Stevens
Affiliations

Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists

Beili Wu et al. Science. .

Abstract

Chemokine receptors are critical regulators of cell migration in the context of immune surveillance, inflammation, and development. The G protein-coupled chemokine receptor CXCR4 is specifically implicated in cancer metastasis and HIV-1 infection. Here we report five independent crystal structures of CXCR4 bound to an antagonist small molecule IT1t and a cyclic peptide CVX15 at 2.5 to 3.2 angstrom resolution. All structures reveal a consistent homodimer with an interface including helices V and VI that may be involved in regulating signaling. The location and shape of the ligand-binding sites differ from other G protein-coupled receptors and are closer to the extracellular surface. These structures provide new clues about the interactions between CXCR4 and its natural ligand CXCL12, and with the HIV-1 glycoprotein gp120.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall fold of the CXCR4/IT1t complex and comparison with other GPCR structures. (A) Overall fold of the CXCR4-2/IT1t. The receptor is colored blue. The N-terminus, ECL1, ECL2 and ECL3 are highlighted in brown, blue, green and red, respectively. The compound IT1t is shown in a magenta stick representation. The disulfide bonds are yellow. Conserved water molecules (67) are shown as red spheres. (B) Comparison of TM helices for CXCR4 (blue), β2AR (PDB ID: 2RH1; yellow), A2AAR (PDB ID: 3EML; green) and rhodopsin (PDB ID: 1U19; pink).
Fig. 2
Fig. 2
CXCR4 ligand-binding cavities for the small molecule IT1t and the cyclic peptide CVX15. (A) CXCR4 ligand-binding cavity for the small molecule IT1t. IT1t (magenta) and the residues of the receptor (green) involved in the ligand interactions are shown in stick representation. Nitrogen atoms are blue and sulfur atoms are yellow. Hydrophobic contacts are shown as green dashed lines, salt bridges are red, and hydrogen bonds are blue. Only the helices involved in the receptor-ligand interaction and part of ECL2 are shown. (B) CXCR4 ligand-binding cavity for the peptide CVX15. The residues of CVX15 (brown) and the residues of the receptor (green) involved in receptor-ligand polar interactions are shown in stick representation. The Cys4-Cys13 disulfide bridge in CVX15 is shown as a yellow stick. Intramolecular hydrogen bonds of CVX15 are shown as purple dashed lines. (C) Schematic representation of the interactions between CXCR4 and IT1t in the ligand binding pocket. Mutations reported to decrease HIV-1 infectivity and disrupt CXCL12 binding and signaling are indicated with blue and yellow squares, respectively (56, 68). (D) Schematic representation of the interactions between CXCR4 and CVX15 in the ligand binding pocket.
Fig. 3
Fig. 3
CXCR4 ligand-binding modes and comparison with other GPCR structures. (A) Comparison of the ligand-binding modes for IT1t and CVX15. CXCR4 molecules in the CXCR4- 2/IT1t and CXCR4-3/CVX15 complexes are colored blue and yellow, respectively. IT1t (magenta) and CVX15 (brown) are shown as sticks. (B) Comparison of the small molecule ligand-binding modes for CXCR4, β2AR (PDB ID: 2RH1), A2AAR (PDB ID: 3EML) and rhodopsin (PDB ID: 1U19). Only CXCR4 helices are shown (blue). The ligands IT1t (for CXCR4, magenta), carazolol (for β2AR, yellow), ZM241385 (for A2AAR, cyan) and retinal (for rhodopsin, green) are shown in stick representation.
Fig. 4
Fig. 4
Dimer interactions in CXCR4-2/IT1t and CXCR4-3/CVX15. (A) Molecular surface representation of the CXCR4 dimer in CXCR4-2/IT1t (blue). (B) Dimer interface in CXCR4-2/IT1t. The surface involved in dimerization is highlighted in dark blue. (C) Molecular surface representation of the CXCR4 dimer in CXCR4-3/CVX15 (yellow). A hypothetical path of the C-terminus, which is not observed in the CXCR4-3/CVX15 structure, is shown as a dashed curve. (D) Dimer interface in CXCR4-3/CVX15. The surface involved in dimer interaction is highlighted in orange. (E) Top view of the extracellular side of the dimers. Two structures show similar interactions via helices V and VI. Residues of CXCR4-2/IT1t involved in the dimer interaction are shown in stick representation, and colored blue in molecule A, cyan in molecule B. (F) Bottom view of the intracellular side of the dimers. Contacts can only be observed at the intracellular tips of helices III and IV, and ICL2 in CXCR4-3/CVX15. The residues of CXCR4-3/CVX15 involved in the dimer interaction are shown in stick representation, and colored yellow and orange. These interactions are not present in the CXCR4/IT1t complex.
Fig. 5
Fig. 5
Stoichiometry of possible CXCR4/CXCL12 binding/signaling complexes. No information on the orientation of CXCL12 with respect to CXCR4 is implied from the models presented. (A) Monomeric CXCR4 binding monomeric CXCL12, (B) dimeric CXCR4 binding monomeric CXCL12, (C) dimeric CXCR4 binding dimeric CXCL12 at either one or both orthosteric sites on each protomer. Alternatively, the 2:2 complex could involve two CXCL12 monomers binding dimeric CXCR4 (not shown). Both CXCR4 and CXCL12 surfaces are colored according to their electrostatic potential from red (negative) to blue (positive), highlighting the charge complementarity of these proteins. The portion of the CXCR4 N-terminal domain (CXCR4-N) present in both the CXCL12 complex (PDB ID: 2K05) and crystal structures of this study is colored yellow, while the remainder is purple (Site 1). Pro27 and the three sulfotyrosines from the CXCR4 N-terminus are represented with space-filling models. The CVX15 peptide (green ribbon) is shown in one CXCR4 receptor per panel and suggests the binding site for Lys1 and the rest of the flexible N-terminal region of CXCL12, which is critical for receptor activation (Site 2). Figures were prepared using ICM software (www.Molsoft.com).
Fig. 6
Fig. 6
Model of early stages of the HIV-1 entry process. (A) Viral entry begins with binding of envelope spikes consisting of a heterotrimer (gp120)3 (gp41)3 (gray wire, EM databank ID: emd_5020 and emd_5023; PDB ID: 3DNO) to CD4 on the surface of host target cells. Glycoprotein gp120 (core structure, cyan, PDB ID: 2QAD) interacts with CD4 (tan, PDB ID: 1WIP and 2KLU). This interaction triggers conformational changes in gp120 that increase the exposure of the third variable loop V3 (magenta) and a region of gp120 between inner and outer domains. CCR5 or CXCR4 (blue) is then recruited as a co-receptor. The number of spikes involved in viral entry and the number of molecules of CD4 or CXCR4 binding to a single spike are unknown; here three CD4 molecules are represented, which results in the close approach of gp120 molecules to the host cell membrane where the interaction with three CXCR4 molecules is depicted. (B) By analogy to a two-site model based on CCR5 (64), the N-terminus of CXCR4 containing sulfotyrosines (site1, circled in yellow) binds first to the base of the V3 loop inducing further conformational changes in gp120 that enable V3 to bind to the extracellular side of CXCR4, primarily ECL2, ECL3 and the ligand-binding cavity (site 2, circled in yellow). CXCR4 residues previously shown to affect gp120 binding are shown as sticks with carbons colored in orange. A hypothetical path of the CXCR4 N-terminus, which is not observed in the current structure, is shown as a blue dashed curve. Only CXCR4 monomers are shown for clarity, although dimers are also possible. Fig. 1, 2, 3, 4 and 6 were prepared using PyMOL.
See this image and copyright information in PMC

Comment in

References

    1. Baggiolini M. Nature. 1998;392:565. - PubMed
    1. Moser B, Wolf M, Walz A, Loetscher P. Trends Immunol. 2004;25:75. - PubMed
    1. Mackay CR. Nat Immunol. 2001;2:95. - PubMed
    1. Ma Q, et al. Proc Natl Acad Sci U S A. 1998;95:9448. - PMC - PubMed
    1. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Nature. 1998;393:595. - PubMed

Publication types